Rimon Therapeutics Ltd.

Rimon Therapeutics Ltd. is a privately-held, biotechnology company based in Toronto, Ontario. It was spun from research being done at the University of Toronto, with the observation of blood vessels growing around an implant.

Initial financing came from the Ontario Centres of Excellence, through the Martin Walmsley Fellowship. A second round of private financing allowed the Company to move to a larger facility in the heart of Toronto’s biotech sector. Rimon has entered into discussions with some of the world’s largest medical device companies.

Rimon is developing synthetic, therapeutic polymers, known as Theramers^TM, that combine bioactivity with a broad range of mechanical and physical properties. Having been designated as devices by the USFDA, Theramers^TM benefit from the shortened timelines required to bring a product to market compared with those of for pharmaceutical products.

Exploited as solids, Theramers^TM deliver localized treatment without any systemic consequences. Their therapeutic applications include inducing the development of new blood vessels, preventing the destruction of tissue, killing bacteria without harming human cells, healing chronic wounds, treating heart disease, delaying knee replacement, and preventing medical device-related infections.

Rimon’s primary product, the MI-Sorb^TM dressing, has entered its first clinical trial and is showing promising, preliminary data. MI-Sorb^TM is used for the treatment of chronic wounds and works by reducing the activity of the high MMP concentrations that “chew apart” chronic wounds faster than they can heal. It can be applied to wounds dry, to provide absorptive capacity for exudating wounds, or can be pre-soaked to support moist wound healing.

MI Theramer^TM – reduces the activity of matrix metalloproteases (MMPs)
Angiogenic Theramer^TM – induces new blood vessel development (angiogenesis)
AM Theramer^TM – destroys gram positive and negative bacteria without harming human cells

Dr. Michael May is an inventor and entrepreneur. He is President and CEO of Rimon Therapeutics Ltd. Dr. May always intended to start a company from the technical richness of academia and in 2000 he co-founded Rimon with his PhD supervisor, Michael Sefton. Dr. May completed his PhD in Biomedical and Chemical Engineering at the University of Toronto in 1998 and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship, in support of the founding of Rimon. Dr. May serves on various biotechnology, commercialization, and academic committees and boards.

Rimon Therapeutics Ltd.
59 Adelaide Street East, Suite 500
Toronto, Ontario, M5C 1K6
Tel. 416-977-2003
Fax 416-977-6383
www.rimontherapeutics.com
info@rimontherapeutics.com